Anacin Tablet
NDC Package 63736-200-91
Package Information
Anacin (asprin and caffeine) tablets is do not use more than directed (see overdose warning)drink a full glass of water with each doseadults and children 12 years of age and older: take 2 tablets every 6 hours; not more than 8 tablets in 24 hours, or as directed by a doctorchildren under 12 years of age: do not use. This formulation utilizes a tablet delivery system. Marketed by Insight Pharmaceuticals Llc, this product is identified by NDC 63736-200 and is authorized under FDA application M013.
Identification & Billing
- RxCUI: 198479 - aspirin 400 MG / caffeine 32 MG Oral Tablet
- RxCUI: 198479 - ASA 400 MG / Caffeine 32 MG Oral Tablet
- RxCUI: 211292 - ANACIN 400 MG / 32 MG Oral Tablet
- RxCUI: 211292 - aspirin 400 MG / caffeine 32 MG Oral Tablet [Anacin]
- RxCUI: 211292 - Anacin (ASA 400 MG / caffeine 32 MG) Oral Tablet
Clinical Specifications
- Anti-Inflammatory Agents, Non-Steroidal - [CS]
- Central Nervous System Stimulant - [EPC] (Established Pharmacologic Class)
- Central Nervous System Stimulation - [PE] (Physiologic Effect)
- Cyclooxygenase Inhibitors - [MoA] (Mechanism of Action)
- Decreased Platelet Aggregation - [PE] (Physiologic Effect)
- Decreased Prostaglandin Production - [PE] (Physiologic Effect)
- Methylxanthine - [EPC] (Established Pharmacologic Class)
- Nonsteroidal Anti-inflammatory Drug - [EPC] (Established Pharmacologic Class)
- Platelet Aggregation Inhibitor - [EPC] (Established Pharmacologic Class)
- Xanthines - [CS]
Regulatory & Marketing
Hierarchy Structure
- 63736 - Insight Pharmaceuticals Llc
- 63736-200 - Anacin
- 63736-200-91 - 1 BOTTLE in 1 BOX / 130 TABLET in 1 BOTTLE
- 63736-200 - Anacin
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (63736-200). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 63736-200-91 identifies a specific commercial package of 1 bottle in 1 box / 130 tablet in 1 bottle of Anacin, a human over the counter drug labeled by Insight Pharmaceuticals Llc. This tablet is formulated for oral use and contains aspirin; caffeine as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Insight Pharmaceuticals Llc on June 25, 2009. The current certification is valid through December 31, 2026.
How is this Insight Pharmaceuticals Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 63736020091. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.
